Fresenius Kabi USA has issued voluntary nationwide recall of four lots of benztropine mesylate injection, USP 2mg/2mL (1mg/mL), in 2mL single dose vials. Being conducted at the user level, the recall is due to the potential presence of ...
APP Pharmaceuticals, a Fresenius Kabi Company, has purchased three products, Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection, from Nexus Pharmaceuticals. As per the agreement, APP acquires complete ...